Lipodystrophy and metabolic complications

CROI 2024: HIV studies with semaglutide: significant benefits but limited access for treatment and research

10 March 2024. Related: Conference reports, Lipodystrophy and metabolic complications.

US guidelines recommend earlier use of statins in people living with HIV

1 March 2024. Related: Guidelines, Lipodystrophy and metabolic complications.

UK surveys on access to New-Fill for facial lipoatrophy

1 October 2023. Related: Side effects, Lipodystrophy and metabolic complications.

>10% weight gain during first two years of ART linked to double the risk of cardiometabolic disease

1 October 2023. Related: Side effects, Lipodystrophy and metabolic complications.

IAS 2023: Metabolic and weight changes using GLP-1 agonists in people living with HIV: need for more data

1 September 2023. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Overview of weight gain, integrase inhibitors and ART

1 June 2023. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Selected webcasts from BHIVA 2023

1 June 2023. Related: Conference reports, Treatment strategies, Side effects, Lipodystrophy and metabolic complications.

IAS 2022: Metabolic complications of newer HIV drugs in older people

1 December 2022. Related: Conference reports, Lipodystrophy and metabolic complications.

INSTIs and cardiovascular events in the RESPOND cohort: early increase at six months normalises after two years

1 July 2022. Related: Side effects, Lipodystrophy and metabolic complications.

Weight changes on ART and how to lose weight successfully

1 June 2021. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, Nutrition.

Tesamorelin for NAFLD in people living with HIV

13 December 2019. Related: Lipodystrophy and metabolic complications, Hepatitis coinfection.

Weight gain and metabolic syndrome with dolutegravir and TAF: results from the ADVANCE trial

15 November 2019. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Over half of mostly black US HIV group has NAFLD – and many have NASH

18 October 2019. Related: Conference reports, Lipodystrophy and metabolic complications.

Type 2 diabetes is often undermanaged in HIV positive people

20 May 2019. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, Coinfections and complications.

INSTI and weight gain: reports from CROI 2019

20 May 2019. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

9th International Workshop on HIV and Ageing

19 October 2018. Related: Conference reports, Lipodystrophy and metabolic complications, Coinfections and complications.

Boosted darunavir is associated with higher cardiovascular risk in D:A:D study, but not atazanavir

8 June 2018. Related: Side effects, Lipodystrophy and metabolic complications.

Reducing risk of myocardial infarction (MI) in HIV positive people

16 April 2018. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, Coinfections and complications.

Low HDL cholesterol is main lipid abnormality in HIV+/HIV- comparison

1 December 2013. Related: Conference reports, Lipodystrophy and metabolic complications.

No association between bone mineral density and lipodystrophy in women receiving antiretroviral therapy

1 February 2011. Related: Conference reports, Antiretrovirals, Women's health, Lipodystrophy and metabolic complications.

Intestinal microflora and low grade metabolic inflammation

1 February 2011. Related: Conference reports, Lipodystrophy and metabolic complications.

Complex connections between bone and fat metabolism

1 February 2011. Related: Conference reports, PK and drug interactions, Lipodystrophy and metabolic complications.

UK studies on bone health: increasedfracture rates reported in HIV-positive people

1 December 2010. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, 4-6 November 2010, London

1 December 2010. Related: Conference reports, Lipodystrophy and metabolic complications.

Bio-Alcamid associated with unacceptable risk of complications: no longer recommended as a treatment for facial lipoatrophy

1 December 2010. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Age raises fracture risk more in HIV-positive people

1 December 2010. Related: Conference reports, Lipodystrophy and metabolic complications.

FDA approves tesamorelin for reduction of central fat accumulation

1 December 2010. Related: Side effects, Lipodystrophy and metabolic complications.

Tesamorelin for reduction of central fat accumulation: regulatory decision delayed in the US

1 October 2010. Related: Side effects, Lipodystrophy and metabolic complications.

75% HIV-positive children have insufficient levels of Vitamin D

1 June 2010. Related: Conference reports, Paediatric care, Side effects, Lipodystrophy and metabolic complications.

High rates of osteopenia and osteoporosis: importance of DEXA monitoring

1 June 2010. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

ACTG 5205: atazanavir/ritonavir vs efavirenz in treatment naive patients

2 April 2010. Related: Conference reports, Antiretrovirals, Side effects, Lipodystrophy and metabolic complications.

Clinical benefits of stopping smoking: CVD and CHD risk returns to that of previous smoker in HIV-positive people within three years

2 April 2010. Related: Conference reports, Lipodystrophy and metabolic complications, Cancer and HIV.

Vitamin D deficiencies in HIV management

2 April 2010. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Central fat accumulation remains a significant problem in patients starting HAART after 2005 with higher incidence in women compared to men

21 February 2010. Related: Conference reports, Women's health, Side effects, Lipodystrophy and metabolic complications.

Gender and race differences in lipodystrophy symptoms

31 December 2009. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Visceral adipose tissue returns to baseline after stopping therapeutic intervention with rHGH

31 December 2009. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Raltegravir body composition study: 48-week DEXA results

31 December 2009. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Lipid and metabolic changes with ARV combinations

5 October 2009. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Haemoglobin A1c (HbA1c) may underestimate glycaemia in patients with diabetes on HIV therapy

26 December 2008. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Statin use in HIV-positive patients

26 December 2008. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

New-fill used to treat lipoatropy in feet

12 June 2008. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results

2 December 2007. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Growth hormone release factor (TH9507) reduces central fat adiposity

4 April 2007. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

d4T associated with significantly increased risk of type-2 diabetes mellitus

6 December 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Switching from PIs to NNRTIs has similar effect on TC/HDL ratio as use of lipid lowering drugs in the management of dyslipidaemia

6 December 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

The role of the metabolic syndrome in HIV

15 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Effect of lifestyle modification on risk factors for cardiovascular disease and metabolic syndrome

9 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Pioglitazone reduces peripheral lipoatrophy and improves adipokines without reducing visceral fat

9 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Interventions for the management of lipodystrophy and metabolic complications

25 March 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Uridine supplement reverses thymidine-induced lipoatrophy

13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Pravastatin increases limb fat in HIV-positive patients with hypercholesterolaemia

13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Evidence that facial fat can return after switching from either d4T or AZT, to abacavir or tenofovir

13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Niacin has beneficial effect on lipids but no reduction in abdominal fat

13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Gluteal implants used to replace lost buttock fat

13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Omega-3 supplement effective to reduce triglycerides

18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Switch to tenofovir from AZT or d4T improves fat loss and improves lipid parameters compared to abacavir

18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Continued use of a thymidine analogue may limit benefit from rosiglitazone when used to treat lipoatrophy

18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Potential for uridine to treat mitochondrial toxicity: still only in vitro data

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

rHGH reduces central fat accumulation in adolescent lipodystrophy

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Pravastatin improves lipid profiles but not endothelial function

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Post navigation